REGENXBIO Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Curran Simpson
- Full Time Employees
- 353
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9804 Medical Center Drive Rockville MD United States of America 20850
- IPO Date
- Sep 17, 2015
- CIK
- 0001590877
- Website
- regenxbio.com
- Similar Companies
- Business
- REGENXBIO Inc. (Nasdaq: RGNX) is a clinical-stage biotechnology company that develops, commercializes, and licenses recombinant adeno-associated virus (rAAV) gene therapies for the treatment of rare and debilitating diseases. The company offers a broad pipeline of product candidates across diverse therapeutic areas, including ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy via suprachoroidal delivery, RGX-121 for the treatment of Hunter syndrome (MPS II), RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-111 for the treatment of fragile X syndrome; it also provides its NAV Technology platform, which licenses proprietary rAAV vectors and capsids to partners such as AbbVie, Novartis, and Sarepta Therapeutics for use in their gene therapy programs. Founded in 2008 and headquartered in Rockville, Maryland, REGENXBIO operates primarily in the United States with a focus on ophthalmology, neurodegeneration, and metabolic diseases, targeting patients with unmet medical needs in rare genetic disorders. In recent developments, REGENXBIO reported positive 2-year data from its Phase I/II AFFINITY trial of ABBV-RGX-314 in patients with advanced wet AMD, demonstrating sustained vision preservation and reduction in anti-VEGF treatment burden. The company also advanced its RGX-121 program with FDA clearance of an investigational new drug application and initiation of the pivotal INSPIRE trial in 2024, alongside dosing the first pediatric patient. Additionally, REGENXBIO expanded its collaboration with AbbVie through a new license agreement for novel AAV capsids and strengthened its manufacturing capabilities with the completion of a state-of-the-art gene therapy facility in 2024 to support commercial-scale production.
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
Regenxbio's muscle disorder therapy meets main goal in late-stage study
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
Faruqi & Faruqi, LLP Highlights Class Action Against REGENXBIO (RGNX) and Upcoming Lead Plaintiff Deadline of April 14, 2026
REGENXBIO DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX
Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm